Genomma Lab Internacional B de C : ISSUED LAB23 & LAB 23-2 UNSECURED BONDS

Relación con Inversionistas

T. [phone]

[e-mail]

GENOMMA LAB INTERNACIONAL SUCCESSFULLY ISSUED

LAB23 & LAB 23-2 UNSECURED BONDS FOR A TOTAL 2.6 BILLION PESOS

PROCEEDS WILL BE USED TO REFINANCE EXISTING DEBT

Transactions were oversubscribed 3.66 and 1.91 times respectively

Mexico City, April 27, 2023 - Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, announces the successful issuance of unsecured Mexican corporate bonds (Cebures) for a total amount of Ps. 2,600,000,000.00 (two billion six hundred thousand Mexican pesos). LAB 23 & LAB 23-2 transactions were oversubscribed 3.66 and 1.91 times respectively and allocated among a diversified investor base.

The issuance was rated "AA+(mex)" for debt in local currency by Fitch Ratings and "HR AA+" by HR Ratings. The transaction details were as follows:

	Concept		LAB 23			LAB 23-2
	Amount (Ps.)	$400,000,000.00		$2,200,000,000.00
	Maturity Date		March 31, 2026			March 30, 2027
		(1,092 days)			(1,456 days)
	Interest Rate		TIIE 28 days + 64pb			TIIE 28 days + 83pb
	Principal Payment			Bullet
	Interest Payment		Every 28 days

Actinver Casa de Bolsa S.A. de C.V., Casa de Bolsa Banorte, S.A. de C.V., Casa de Bolsa BBVA México S.A. de C.V., Casa de Bolsa Santander S.A. de C.V., Intercam Casa de Bolsa, S.A. de C.V. and Scotia Inverlat Casa de Bolsa, S.A. de C.V. acted as joint book-runners for the issuance. As placement union acted: Valores Mexicanos Casa de Bolsa, S.A. de C.V. Finally, CIBANCO, S.A., Institución de Banca Múltiple acted as common representative.

The proceeds will be used for the use funds outlined in the supplemental prospectus of each issuance, which include, among others, the full prepayment of the LAB 20 Cebur, strengthening the Company's financial debt maturity profile and further optimizing the average liabilities duration.

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low‐cost, highly flexible supply chain operating model. For more information visit: www.genommalab.com

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" (Bloomberg: LABB:MM).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company's related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

https://inversionistas.genommalab.com

1